Ad19a/64 Adenoviral Vector
Ad19a/64 vector for vaccination
Our proprietary Ad19a/64 vector (Subtype D) can be used to overcome the low transduction efficiency of commonly used Ad serotypes and help overcome the challenge of pre-existing immunity. It is an attractive alternative for the most commonly used human adenovirus type 5 (Ad5) for specific types of applications.
Ad19a/64 is the first accessible subtype D adenovirus vector. This vector provides superior transduction of human cells (e.g., dendritic cells, cardiomyocytes, fibroblasts, PBMCs, myoblasts, and myotubes) when compared to Ad5. It also possesses CAR-independent binding properties, targeting sialic acid-dependent receptors. In preclinical vaccine studies, the vector induced superior levels of CD4 and CD8 immune responses in non-human primates.
Key benefits of our Ad19a/64 vector
Transduction experiments with human myoblasts and primary myotubes
Ad19a/64 in mucosal boost immunization against SARS-CoV-2
Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.